Company Filing History:
4 out of 260 
4 out of 7 Years Active: 2015-2019
Title: Innovator Yoo Chang Park: Pioneering Therapies for Hunter Syndrome
Introduction
Yoo Chang Park, a prominent inventor based in Yongin-si, South Korea, has made significant contributions to the field of biotechnology with a focus on therapeutic solutions for rare diseases. With four patents to his name, Park's work is particularly notable for its impact on treatments for Hunter Syndrome, a genetic disorder.
Latest Patents
Among his latest innovations, Park developed a composition and formulation comprising recombinant human iduronate-2-sulfatase (IDS) along with a preparation method. His patented formulations not only exhibit a distinct glycosylation pattern and formylglycine content compared to ELAPRASE® but also demonstrate superior pharmaceutical efficacy and safety. These advancements position his compositions as promising candidates for effective therapy against Hunter Syndrome, providing hope for those affected by this rare disease.
Career Highlights
Throughout his career, Yoo Chang Park has worked with esteemed organizations in the biotechnology sector. He has been associated with The Green Cross Corporation and Medigenebio Corporation, where he contributed to groundbreaking research and development projects. His dedication to innovation in this arena is reflected in his successful patent applications.
Collaborations
Collaboration has been a key aspect of Park's career, as he has worked alongside talented professionals including Thong-Gyu Jin and Yo Kyung Chung. Their joint efforts have played a crucial role in the development of therapeutic products aimed at addressing unmet medical needs.
Conclusion
Yoo Chang Park's work exemplifies the spirit of innovation in the biotechnology field. His contributions, particularly in relation to the treatment of Hunter Syndrome, underscore the importance of research and development in improving patient outcomes. As he continues to advance his inventions, Park remains a pivotal figure in the quest for effective therapies for rare genetic disorders.